Teacher Retirement System of Texas Trims Stake in Eli Lilly and Company $LLY

Teacher Retirement System of Texas lowered its position in Eli Lilly and Company (NYSE:LLY) by 4.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 290,865 shares of the company’s stock after selling 13,379 shares during the quarter. Eli Lilly and Company comprises approximately 0.9% of Teacher Retirement System of Texas’ portfolio, making the stock its 13th largest holding. Teacher Retirement System of Texas’ holdings in Eli Lilly and Company were worth $221,930,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Hudson Value Partners LLC boosted its position in shares of Eli Lilly and Company by 13.1% during the 3rd quarter. Hudson Value Partners LLC now owns 2,770 shares of the company’s stock valued at $2,114,000 after acquiring an additional 321 shares during the last quarter. UNIVEST FINANCIAL Corp raised its stake in Eli Lilly and Company by 24.2% in the third quarter. UNIVEST FINANCIAL Corp now owns 34,297 shares of the company’s stock valued at $26,169,000 after purchasing an additional 6,678 shares in the last quarter. Kingdom Financial Group LLC. bought a new stake in Eli Lilly and Company during the third quarter valued at approximately $492,000. Vantage Investment Partners LLC grew its stake in Eli Lilly and Company by 5.8% in the 3rd quarter. Vantage Investment Partners LLC now owns 51,825 shares of the company’s stock worth $39,542,000 after buying an additional 2,819 shares in the last quarter. Finally, Coign Capital Advisors LLC grew its stake in Eli Lilly and Company by 8.4% in the 3rd quarter. Coign Capital Advisors LLC now owns 855 shares of the company’s stock worth $652,000 after buying an additional 66 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on LLY. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Leerink Partners set a $1,234.00 target price on Eli Lilly and Company in a research note on Monday, January 5th. Cantor Fitzgerald restated an “overweight” rating on shares of Eli Lilly and Company in a research report on Monday, December 1st. Jefferies Financial Group lifted their price target on Eli Lilly and Company from $976.00 to $1,300.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Finally, Scotiabank started coverage on Eli Lilly and Company in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $1,165.00 price objective for the company. Four analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $1,174.61.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,087.63 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The company has a market capitalization of $1.03 trillion, a PE ratio of 53.21, a P/E/G ratio of 0.81 and a beta of 0.35. The firm has a fifty day simple moving average of $1,056.39 and a two-hundred day simple moving average of $878.04. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same period last year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is currently 29.35%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA granted Breakthrough Therapy designation for Lilly’s ovarian cancer candidate (sofetabart/mipitecan), improving the odds of faster development and a premium approval pathway for a novel oncology asset. Lilly receives FDA’s breakthrough therapy designation for ovarian cancer drug
• Positive Sentiment: Lilly launched a Phase 3b dosing study for retatrutide (obesity candidate), a near-term program de?risk step that could support label expansion and broaden commercial use if results are favorable. Eli Lilly Advances Retatrutide With New Phase 3b Obesity Dosing Study
• Positive Sentiment: Data/real?world studies continue to support obesity and metabolic franchises: SURMOUNT?REAL UK (tirzepatide real?world) updates and a retatrutide osteoarthritis signal suggest incremental clinical and commercial benefits beyond weight loss. These help underpin revenue upside for GLP/GIP drugs. Lilly’s SURMOUNT-REAL UK Trial: Real-World Test of Tirzepatide’s Obesity Upside
• Positive Sentiment: Lilly expanded its oncology imaging footprint with a new Phase 1 PET tracer study, signaling diversification into diagnostics/precision oncology that can boost long?term margins and pipeline value. Eli Lilly Expands Oncology Imaging Footprint With New Phase 1 PET Tracer Study
• Positive Sentiment: Executives at the JPMorgan Healthcare Conference reiterated that the obesity market will evolve to include more pill options, combos and better access — a structural message that supports multi?year demand growth for Lilly’s metabolic portfolio. What obesity drugmakers see next in the market: More pills, easier access and drug combinations
• Neutral Sentiment: Lilly confirmed its fourth?quarter 2025 earnings release and conference call for Feb. 4 — a scheduled event that will likely drive near?term volatility as investors re?assess guidance and sales cadence. Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement
• Neutral Sentiment: Organizational update: Lilly appointed Pranav Shroff as director of marketing — a routine personnel move with limited near?term financial impact but relevant for commercial execution. Eli Lilly appoints Pranav Shroff as director of marketing
• Negative Sentiment: Competition risk in key international markets: Sun Pharma won approval for a Wegovy generic in India, intensifying price and market?share pressure in a top growth region and foreshadowing similar generic/biologic competition scenarios. Eli Lilly, Novo Nordisk Set for Fierce Battle in India’s Obesity Drug Market as Sun Pharma Wins Wegovy Generic Nod
• Negative Sentiment: Legal/political overhang: coverage cites a lawsuit and public scrutiny over insulin pricing that can bring reputational and financial risk if litigation expands or results in penalties. Rokita Discusses Lawsuit Against Eli Lilly & Insulin Prices

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.